ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 364

Serum Sclerostin Levels in Rheumatoid Arthritis (RA) and Its Correlation with Disease Activity and Bone Mineral Density

Rashmi ranjan Sahoo Sr.1, Urmila Dhakad2, Siddharth K. Das3, Ragini Srivastava4, Saumya Ranjan Tripathy5, Durgesh Srivastava6 and Harikrishnan Velayudhan7, 1Rheumatology, King George Medical University, Lucknow, India, 2Rheumatology, Asst Professor, K.G. Medical University, Lucknow, India, Lucknow, India, 3Rheumatology, Prof. and Head, Rheumatology, K.G. Medical University, Lucknow, Lucknow, India, 4Rheumatology, Senior Research Officer, Rheumatology, K.G. Medical University, Lucknow, India, Lucknow, India, 5KGMU, Lucknow, India, Lucknow, India, 6Rheumatology, King Georges Medical Univesity, Lucknow, India, 7Rheumatology, Senior Resident, Rheumatology, K.G. Medical University, Lucknow, India, Luknow, India

Meeting: 2016 ACR/ARHP Annual Meeting

Date of first publication: September 28, 2016

Keywords: Rheumatoid arthritis (RA)

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print
Session Information

Date: Sunday, November 13, 2016

Title: Osteoporosis and Metabolic Bone Disease – Clinical Aspects and Pathogenesis - Poster

Session Type: ACR Poster Session A

Session Time: 9:00AM-11:00AM

Background/Purpose: Sclerostin, an osteocyte secreted protein encoded by SOST gene, is an important regulator of Wnt pathway. It prevents bone formation by blocking Wnt binding to its receptor. High levels of sclerostin have been reported in post-menopausal women with osteoporosis. Sclerostin can be induced during inflammation and may also inhibit repair of bone erosion in patients with rheumatoid arthritis (RA). There are few studies demonstrating the role of sclerostin on bone mass and disease activity in RA patients. This study aims to assess the serum sclerostin level in patients with RA and to correlate its level with disease activity and bone mineral density.

Methods: Forty-seven patients of RA fulfilling the ACR/EULAR (2010) criteria, attending the department of Rheumatology, King George Medical University, Lucknow, India were included in the study. Twenty-eight age- and sex-matched healthy controls were enrolled from the same geographic area. Apart from routine blood investigations; rheumatoid factor (RF), anti citrullinated protein antibody (ACPA), 25 hydroxy vitamin D, radiographs and bone mineral density (BMD) were also done. Disease activity was assessed by CDAI. Serum sclerostin levels of both cases and controls was assayed by using enzyme-linked immunosorbent assay (ELISA) assay [Elabscience, coefficient of variation (CV) < 10%] and compared with disease activity and bone mineral density.

Results: Mean age of RA patients was 32.7+6.8 yrs with mean duration of disease 4.2+2 yrs. Mean age of the control group was 28.7+6.3 yrs. Rheumatoid factor was positive in 29 out of 38 patients and anti citrullinated protein antibody was positive in 44 out of 47 patients. Mean sclerostin level among patients was 8422+3655 and that of control group was 6479+1510 (p value 0.002). Serum sclerostin level did not correlate significantly with ESR (r:-0.31, p:0.048), CRP (r:-0.11, p:0.65), CDAI (r:-0.11, p:0.45), BMD at lumbar spine(L1-4, r:.14, p:0.35) and femur (r:0.06, p: 0.67).

Conclusion: Serum sclerostin level did not correlate with disease activity and BMD in RA patients.


Disclosure: R. R. Sahoo Sr., None; U. Dhakad, None; S. K. Das, None; R. Srivastava, None; S. R. Tripathy, None; D. Srivastava, None; H. Velayudhan, None.

To cite this abstract in AMA style:

Sahoo RR Sr., Dhakad U, Das SK, Srivastava R, Tripathy SR, Srivastava D, Velayudhan H. Serum Sclerostin Levels in Rheumatoid Arthritis (RA) and Its Correlation with Disease Activity and Bone Mineral Density [abstract]. Arthritis Rheumatol. 2016; 68 (suppl 10). https://acrabstracts.org/abstract/serum-sclerostin-levels-in-rheumatoid-arthritis-ra-and-its-correlation-with-disease-activity-and-bone-mineral-density/. Accessed .
  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to 2016 ACR/ARHP Annual Meeting

ACR Meeting Abstracts - https://acrabstracts.org/abstract/serum-sclerostin-levels-in-rheumatoid-arthritis-ra-and-its-correlation-with-disease-activity-and-bone-mineral-density/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology